A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain‐derived synaptic plasticity‐disrupting Aβ
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
J. Neurochem. (2011) 119, 189–201. Diverse lines of evidence indicate that pre‐fibrillar, diffusible assemblies of the amyloid β‐protein (Aβ) play an important role in Alzheimer’s disease pathogenesis. Although the precise molecular identity of these soluble toxins remains unsettled, recent experiments suggest that sodium dodecyl sulfate (SDS)‐stable Aβ dimers may be the basic building blocks of Alzheimer’s disease‐associated synaptotoxic assemblies and as such present an attractive target for therapeutic intervention. In the absence of sufficient amounts of highly pure cerebral Aβ dimers, we have used synthetic disulfide cross‐linked dimers (free of Aβ monomer or fibrils) to generate conformation‐specific monoclonal antibodies. These dimers aggregate to form kinetically trapped protofibrils, but do not readily form fibrils. We identified two antibodies, 3C6 and 4B5, which preferentially bind assemblies formed from covalent Aβ dimers, but do not bind to Aβ monomer, amyloid precursor protein, or aggregates formed by other amyloidogenic proteins. Monoclonal antibody 3C6, but not an IgM isotype‐matched control antibody, ameliorated the plasticity‐disrupting effects of Aβ extracted from the aqueous phase of Alzheimer’s disease brain, thus suggesting that 3C6 targets pathogenically relevant Aβ assemblies. These data prove the usefulness of covalent dimers and their assemblies as immunogens and recommend further investigation of the therapeutic and diagnostic utility of monoclonal antibodies raised to such assemblies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 2×
“Numerous studies have shown that water-soluble non-fibrillar Aβ assemblies are toxic and impair disease-relevant models of synaptic form and function (Lambert et al., 1998; Walsh et al., 1999; Walsh et al., 2002; Barghorn et al., 2005; Cleary et al., 2005; Lesne et al., 2006; Lacor et al., 2007; Martins et al., 2008;…”
BackgroundRetractedDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“Pathologically, AD is characterized by the presence of extracellular amyloid plaques, intraneuronal neurofibrillary tangles and synaptic loss throughout the limbic and association cortices (Alzheimer 1906; Kidd 1964; Khachaturian 1985; Hardy and Allsop 1991; Selkoe 1991).”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“The amyloid b-protein (Ab) is the primary constituent of amyloid plaques and a plethora of genetic, animal modeling and biochemical data indicate that Ab plays a central role in AD pathogenesis (Walsh and Selkoe 2007).”
BackgroundSelf-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · cited 2×
“Given the enormous interest in Aβ-specific antibodies as therapeutic, diagnostic, and basic research reagents, numerous antibodies have been generated and these can be grouped into 4 classes based on their ability to recognize: (1) linear epitopes (Seubert et al., 1992; Solomon et al., 1996; Jensen et al., 2000), (2)…”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · cited 2×
“…number of studies have demonstrated that both the active generation or passive transfer of anti-Ab antibodies can prevent or reverse Ab-induced cognitive impairment in APP transgenic mice (Games et al. 2006) and this has prompted several clinical trials in humans (Schenk 2002; Gilman et al. 2005).”
BackgroundLacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 2×
“Numerous studies have shown that water-soluble non-fibrillar Aβ assemblies are toxic and impair disease-relevant models of synaptic form and function (Lambert et al., 1998; Walsh et al., 1999; Walsh et al., 2002; Barghorn et al., 2005; Cleary et al., 2005; Lesne et al., 2006; Lacor et al., 2007; Martins et al., 2008;…”
BackgroundAmyloid β-Protein Fibrillogenesis
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046 · cited 2×
“Numerous studies have shown that water-soluble non-fibrillar Aβ assemblies are toxic and impair disease-relevant models of synaptic form and function (Lambert et al., 1998; Walsh et al., 1999; Walsh et al., 2002; Barghorn et al., 2005; Cleary et al., 2005; Lesne et al., 2006; Lacor et al., 2007; Martins et al., 2008;…”
BackgroundSelf-citationPicomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740 · cited 1×
“This approach suffers from the loss of antibody capacity due to binding to non-pathogenic forms of Ab and removal of ‘useful’ Ab (Arancio and Chao 2007; Puzzo et al. 2008).”
BackgroundWater-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618 · cited 1×
“Highly stable Ab dimers are specifically found in AD brain and blood (Kuo et al. 1996; Roher et al. 1996; Mc Donald et al. 2010; Villemagne et al. 2010), and brainderived dimers have been shown to block long-term potentiation (LTP), inhibit synapse remodeling, and impair memory consolidation…”
BackgroundBarghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03407.x · Cited by 559
Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436
Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid
Vigo‐Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09841.x · Cited by 385
Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering
Sandberg, A., Luheshi, L. M., Söllvander, S., Pereira de Barros, T., Macao, B., Knowles, T. P. J., Biverstål, H., Lendel, C., Ekholm-Petterson, F., Dubnovitsky, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001740107 · Cited by 358 · cited 2×
“Although, it is not yet known which assembly form(s) of Aβ are the proximate pathogens, recent attention has focused on various forms of Aβ dimers (Shankar et al., 2008; Kok et al., 2009; Sandberg et al., 2010).”
BackgroundVaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies
Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00592.x · Cited by 349 · cited 2×
“, 2000), (2) conformational epitopes exposed on all aggregated Aβ species (Lambert et al., 2001; Lee et al., 2006; Englund et al., 2007; Lambert et al., 2007), (3) epitopes on only a subset of Aβ assemblies (Barghorn et al.”
BackgroundAmyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · cited 2×
“Notably, Aβ dimer adsorption onto surfaces and the subsequent exposure of cryptic conformational epitopes may be physiologically relevant since in vivo Aβ is thought to be bound to proteins such as albumin (Biere et al., 1996), and the blood-borne dimeric peptide is purported to be exclusively present on cellular memb…”
BackgroundKlyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321 · cited 4×
“…and blood (Kuo et al. 1996; Roher et al. 1996; Mc Donald et al. 2010; Villemagne et al. 2010), and brainderived dimers have been shown to block long-term potentiation (LTP), inhibit synapse remodeling, and impair memory consolidation (Klyubin et al. 2008; Shankar et al. 2008; Freir et al. 2011).”
BackgroundMethodInfluentialSelf-citationMonoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 3×
“The pan-Ab aggregate specificity of 3C6 and its ability to neutralize toxic human brain-derived Ab is akin to the antiamyloidogenic activity of previously described antibodies (Lambert et al. 2001, 2007; Lee et al. 2006; Englund et al. 2007).”
BackgroundSensitive ELISA detection of amyloid‐β protofibrils in biological samples
Englund, H., Sehlin, D., Johansson, A., Nilsson, L. N. G., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04759.x · Cited by 292 · cited 4×
“The pan-Ab aggregate specificity of 3C6 and its ability to neutralize toxic human brain-derived Ab is akin to the antiamyloidogenic activity of previously described antibodies (Lambert et al. 2001, 2007; Lee et al. 2006; Englund et al. 2007).”
BackgroundInfluentialAmyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
O'Nuallain, B., Freir, D. B., Nicoll, A. J., Risse, E., Ferguson, N., Herron, C. E., Collinge, J., & Walsh, D. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3537-10.2010 · Cited by 259
Self-citationMelchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202 · cited 4×
“The latter were used because injected Ab is much less well cleared in tPA mice (Melchor et al. 2003) thus offering the possibility of more prolonged exposure to the Ab immunogen and the potential for a stronger immune response.”
BackgroundMethodInfluentialGeneration and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies
Hillen, H., Barghorn, S., Striebinger, A., Labkovsky, B., Müller, R., Nimmrich, V., Nolte, M. W., Perez-Cruz, C., van der Auwera, I., van Leuven, F., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5721-09.2010 · Cited by 113
Cited by
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., & Mahmoudi, J. (2015) · Medical Principles and Practice · doi:10.1159/000369101 · Cited by 537
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Hu, N.-W., Nicoll, A. J., Zhang, D., Mably, A. J., O’Malley, T., Purro, S. A., Terry, C., Collinge, J., Walsh, D. M., & Rowan, M. J. (2014) · Nature Communications · doi:10.1038/ncomms4374 · Cited by 193
Self-citation
Metadata
- Authors
- O’Nuallain, B., Klyubin, I., Mc Donald, J. M., Foster, J. S., Welzel, A., Barry, A., Dykoski, R. K., Cleary, J. P., Gebbink, M. F. B. G., Rowan, M. J., & Walsh, D. M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-08-22
- Volume
- 119
- Issue
- 1
- Pages
- 189-201
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1580458257
- Cited by
- 30
- References
- 21
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.